Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 9/20 | 0.48 |
| ▸ | CA2 | P00918 | 9/20 | 0.48 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509845 | 0.97 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL13968020 | 0.90 | MEN1 (0.49) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL31250630 | 0.90 | MEN1 (0.54) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL4388456 | 0.90 | MEN1 (0.46) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL24983130 | 0.89 | MEN1 (0.48) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL13146976 | 0.89 | TDP1 (0.49) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL1509861 | 0.88 | MEN1 (0.45) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL4394882 | 0.88 | MEN1 (0.53) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL31045243 | 0.87 | TDP1 (0.57) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL18484173 | 0.87 | TSHR (0.53) | MEN1GAAKMT2ATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386572-B1 | Insulin derivative | NOVO NORDISK AS (DK) | 2015-07-08 | — | — | EP | disclosed |
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-8933021-B2 | Insulin derivative | NOVO NORDISK A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-8859493-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-10-14 | — | — | US | disclosed |
| US-8859493-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-10-14 | — | — | US | disclosed |
| EP-2292653-B1 | Novel insulin derivatives | NOVO NORDISK AS (DK) | 2014-05-21 | — | — | EP | disclosed |
| EP-1846447-B1 | INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2013-08-21 | — | — | EP | disclosed |
| EP-2015770-B1 | INSULIN DERIVATIVE | NOVO NORDISK AS (DK) | 2012-09-26 | — | — | EP | disclosed |
| US-20120208749-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-08-16 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090239785-A1 | Insulin Derivative | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| EP-2015770-A2 | INSULIN DERIVATIVE | Novo Nordisk A/S (DK) | 2009-01-21 | — | — | EP | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
| WO-2007128817-A2 | INSULIN DERIVATIVE | NOVO NORDISK A/S (DK) | 2007-11-15 | — | — | WO | disclosed |
| EP-1846447-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082205-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239785-A1 | Insulin Derivative | IAPP, INSR, GPR119 | MEN1 540/4885GAA 444/4885KMT2A 4569/4885 |
| US-20120208749-A1 | Insulin derivatives | IAPP, INSR, GCG | MEN1 1847/4885GAA 788/4885KMT2A 4370/4885 |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | MEN1 2390/4885GAA 1395/4885KMT2A 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.